Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital

Autor: Emily Lowery, Kimberly Saddler, Miguel Sierra-Hoffman, Miriams T. Castro-Lainez, Jennifer Sul, Mark L. Stevens, Sheryl Kosler, Pruthvi Patel, Jason Zhang
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Bacterial Diseases
Male
0301 basic medicine
Lipoglycopeptide
Antibiotics
Skin infection
chemistry.chemical_compound
Medical Conditions
Electronics Engineering
0302 clinical medicine
Outpatients
Medicine and Health Sciences
Clinical endpoint
030212 general & internal medicine
Abscess
Aged
80 and over
Multidisciplinary
Antimicrobials
Drugs
Middle Aged
Hospitals
Anti-Bacterial Agents
Infectious Diseases
Treatment Outcome
Cellulitis
Comparators
Engineering and Technology
Medicine
Female
Research Article
Skin Infections
Adult
medicine.medical_specialty
Patients
medicine.drug_class
Science
030106 microbiology
Dermatology
Microbiology
Skin Diseases
Patient Readmission
Young Adult
03 medical and health sciences
Signs and Symptoms
Microbial Control
Internal medicine
medicine
Humans
Aged
Retrospective Studies
Pharmacology
Inpatients
business.industry
Oritavancin
Lipoglycopeptides
Biology and Life Sciences
Retrospective cohort study
Skin Diseases
Bacterial
medicine.disease
Health Care
Abscesses
chemistry
Health Care Facilities
Electronics
Clinical Medicine
business
Zdroj: PLoS ONE, Vol 16, Iss 3, p e0248129 (2021)
PLoS ONE
ISSN: 1932-6203
Popis: Background Oritavancin is a lipoglycopeptide antibiotic with in vitro bactericidal activity against gram-positive pathogens indicated for use in adults with acute bacterial skin and skin structure infections (ABSSSI). Its concentration-dependent activity and prolonged half-life provide a convenient single-dose alternative to multi-dose daily therapies for ABSSSI. This retrospective cohort study was conducted to quantify the clinical and economic advantages of using oritavancin compared to other antibiotic agents that have been historically effective for ABSSSI. Methods Seventy-nine patients received oritavancin who had failed previous outpatient antibiotic therapy (OPAT) for cellulitis or abscess and were subsequently readmitted to the hospital as an inpatient between 2016 and 2018. These patients were compared to a cohort of 28 patients receiving other antibiotics following OPAT failure and subsequent hospitalization for these two infection types. The primary clinical end point was average length of stay (aLOS) and secondary endpoints included readmission rates for the same indication at 30 and 90 days after discharge and the average hospital cost (aHC). Results A total of 107 patients were hospitalized for treatment of cellulitis or abscess. Demographic characteristics of both the oritavancin and comparator groups were similar except for the presence of diabetes. The primary clinical endpoint showed a non-significant decrease in aLOS between the oritavancin group versus comparator (2.12 days versus 2.59 days; p = 0.097). The secondary endpoints revealed lower readmission rates associated with oritavancin treatment at 30 and 90 days; the average hospital cost was 5.9% lower for patients that received oritavancin. Conclusion The results of this study demonstrate that oritavancin provides not only a single-dose alternative to multi-day therapies for skin and skin structure infections, but also a clinical and economic advantage compared to other antibiotic agents.
Databáze: OpenAIRE
Externí odkaz: